Cargando…

The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia

Hematological malignancies possess a distinctive immunologic microenvironment compared with solid tumors. Here, using an established computational algorithm (CIBERSORT), we systematically analyzed the overall distribution of 22 tumor-infiltrating leukocyte (TIL) populations in more than 2000 bone ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zi-Jun, Gu, Yu, Wang, Cui-Zhu, Jin, Ye, Wen, Xiang-Mei, Ma, Ji-Chun, Tang, Li-Juan, Mao, Zhen-Wei, Qian, Jun, Lin, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959428/
https://www.ncbi.nlm.nih.gov/pubmed/32002295
http://dx.doi.org/10.1080/2162402X.2019.1683347
_version_ 1783487595632656384
author Xu, Zi-Jun
Gu, Yu
Wang, Cui-Zhu
Jin, Ye
Wen, Xiang-Mei
Ma, Ji-Chun
Tang, Li-Juan
Mao, Zhen-Wei
Qian, Jun
Lin, Jiang
author_facet Xu, Zi-Jun
Gu, Yu
Wang, Cui-Zhu
Jin, Ye
Wen, Xiang-Mei
Ma, Ji-Chun
Tang, Li-Juan
Mao, Zhen-Wei
Qian, Jun
Lin, Jiang
author_sort Xu, Zi-Jun
collection PubMed
description Hematological malignancies possess a distinctive immunologic microenvironment compared with solid tumors. Here, using an established computational algorithm (CIBERSORT), we systematically analyzed the overall distribution of 22 tumor-infiltrating leukocyte (TIL) populations in more than 2000 bone marrow (BM) samples from 5 major hematological malignancies and healthy controls. Focusing on significantly altered TILs in acute myeloid leukemia (AML), we found that patients with AML exhibited increased frequencies of M2 macrophages, compared to either healthy controls or the other four malignancies. High infiltration of M2 macrophages was associated with poor outcome in AML. Further analysis revealed that CD206, a M2 marker gene, could faithfully reflect variation in M2 fractions and was more highly expressed in AML than normal controls. High CD206 expression predicted inferior overall survival (OS) and event-free survival (EFS) in two independent AML cohorts. Among 175 patients with intermediate-risk cytogenetics, the survival still differed greatly between low and high CD206 expressers (OS; P < .0001; 3-year rates, 56% v 32%; EFS; P < .001; 3-year rates, 47% v 25%). When analyzed in a meta-analysis, CD206 as a continuous variable showed superior predictive performance than classical prognosticators in AML (BAALC, ERG, EVI1, MN1, and WT1). In summary, M2 macrophages are preferentially enriched in AML. The M2 marker CD206 may serve as a new prognostic marker in AML.
format Online
Article
Text
id pubmed-6959428
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-69594282020-01-30 The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia Xu, Zi-Jun Gu, Yu Wang, Cui-Zhu Jin, Ye Wen, Xiang-Mei Ma, Ji-Chun Tang, Li-Juan Mao, Zhen-Wei Qian, Jun Lin, Jiang Oncoimmunology Original Research Hematological malignancies possess a distinctive immunologic microenvironment compared with solid tumors. Here, using an established computational algorithm (CIBERSORT), we systematically analyzed the overall distribution of 22 tumor-infiltrating leukocyte (TIL) populations in more than 2000 bone marrow (BM) samples from 5 major hematological malignancies and healthy controls. Focusing on significantly altered TILs in acute myeloid leukemia (AML), we found that patients with AML exhibited increased frequencies of M2 macrophages, compared to either healthy controls or the other four malignancies. High infiltration of M2 macrophages was associated with poor outcome in AML. Further analysis revealed that CD206, a M2 marker gene, could faithfully reflect variation in M2 fractions and was more highly expressed in AML than normal controls. High CD206 expression predicted inferior overall survival (OS) and event-free survival (EFS) in two independent AML cohorts. Among 175 patients with intermediate-risk cytogenetics, the survival still differed greatly between low and high CD206 expressers (OS; P < .0001; 3-year rates, 56% v 32%; EFS; P < .001; 3-year rates, 47% v 25%). When analyzed in a meta-analysis, CD206 as a continuous variable showed superior predictive performance than classical prognosticators in AML (BAALC, ERG, EVI1, MN1, and WT1). In summary, M2 macrophages are preferentially enriched in AML. The M2 marker CD206 may serve as a new prognostic marker in AML. Taylor & Francis 2019-11-03 /pmc/articles/PMC6959428/ /pubmed/32002295 http://dx.doi.org/10.1080/2162402X.2019.1683347 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Xu, Zi-Jun
Gu, Yu
Wang, Cui-Zhu
Jin, Ye
Wen, Xiang-Mei
Ma, Ji-Chun
Tang, Li-Juan
Mao, Zhen-Wei
Qian, Jun
Lin, Jiang
The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia
title The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia
title_full The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia
title_fullStr The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia
title_full_unstemmed The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia
title_short The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia
title_sort m2 macrophage marker cd206: a novel prognostic indicator for acute myeloid leukemia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959428/
https://www.ncbi.nlm.nih.gov/pubmed/32002295
http://dx.doi.org/10.1080/2162402X.2019.1683347
work_keys_str_mv AT xuzijun them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT guyu them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT wangcuizhu them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT jinye them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT wenxiangmei them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT majichun them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT tanglijuan them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT maozhenwei them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT qianjun them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT linjiang them2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT xuzijun m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT guyu m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT wangcuizhu m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT jinye m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT wenxiangmei m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT majichun m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT tanglijuan m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT maozhenwei m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT qianjun m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia
AT linjiang m2macrophagemarkercd206anovelprognosticindicatorforacutemyeloidleukemia